知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

32 条记录 (耗时 0.069 秒)

    SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION
    2.
    发明申请
    SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION 审中-公开
    HEPATITIS C VIRUS REPLICATION的替代性抑制抑制剂

    公开(公告)号：US20120095211A1

    公开(公告)日：2012-04-19

    申请号：US13237843

    申请日：2011-09-20

    申请人： Brad Buckman ,  John B. Nicholas ,  Vladimir Serebryany ,  Scott D. Seiwert

    发明人： Brad Buckman ,  John B. Nicholas ,  Vladimir Serebryany ,  Scott D. Seiwert

    IPC分类号： C07D487/04

    CPC分类号： C07K5/0808 ,  A61K31/407 ,  C07D209/42 ,  C07D401/12 ,  C07D403/12 ,  C07D417/14 ,  C07D487/04 ,  C07D498/18

    摘要： The embodiments provide compounds of the general Formulae I, Ia, II, IIa, III, IIIa, IIIb, IV, IVa, IVb, V, Va, Vb, VI, VIa, VIb, and VIc, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. The embodiments also provide methods for the synthesis of subject compounds and intermediates in the synthetic methods.

    摘要翻译： 实施方案提供了通式I，Ia，II，IIa，III，IIIa，IIIb，IV，IVa，IVb，V，Va，Vb，VI，VIa，VIb和VIc的化合物，以及包括药物 组合物，包含主题化合物。 实施方案还提供治疗方法，包括治疗丙型肝炎病毒感染的方法和治疗肝纤维化的方法，所述方法通常涉及向有需要的个体施用有效量的主题化合物或组合物。 实施方案还提供合成方法中合成主题化合物和中间体的方法。

    Use of Alpha-Glucosidase Inhibitors to Treat Alphavirus Infections
    7.
    发明申请
    Use of Alpha-Glucosidase Inhibitors to Treat Alphavirus Infections 审中-公开
    使用α-葡萄糖苷酶抑制剂治疗甲病毒感染

    公开(公告)号：US20110177026A1

    公开(公告)日：2011-07-21

    申请号：US13024915

    申请日：2011-02-10

    申请人： Lawrence M. Blatt ,  Hua Tan ,  Scott D. Seiwert

    发明人： Lawrence M. Blatt ,  Hua Tan ,  Scott D. Seiwert

    IPC分类号： A61K38/21 ,  A61K31/70 ,  A61K31/702 ,  A61K31/445

    CPC分类号： A61K31/7008 ,  A61K31/445 ,  A61K31/7034 ,  A61K38/21 ,  A61K45/06 ,  A61K2300/00

    摘要： The present invention provides methods for treating a flavivirus infection, including hepatitis C virus (HCV) infection, in an individual suffering from a flavivirus infection. In some embodiments, the methods involve administering to an individual in need thereof an effective amount of an agent that inhibits enzymatic activity of a membrane-bound α-glucosidase inhibitor. In other embodiments, the methods involve administering to an individual in need thereof effective amounts of an α-glucosidase inhibitor and at least one additional therapeutic agent.

    摘要翻译： 本发明提供了在患有黄病毒感染的个体中治疗黄病毒感染（包括丙型肝炎病毒（HCV）感染）的方法。 在一些实施方案中，所述方法包括向有需要的个体施用有效量的抑制膜结合的α-葡糖苷酶抑制剂的酶活性的试剂。 在其它实施方案中，所述方法包括向有需要的个体施用有效量的α-葡糖苷酶抑制剂和至少一种另外的治疗剂。

    Hyperglycosylated polypeptide variants and methods of use
    8.
    发明授权
    Hyperglycosylated polypeptide variants and methods of use 有权

    公开(公告)号：US07597884B2

    公开(公告)日：2009-10-06

    申请号：US11351163

    申请日：2006-02-08

    申请人： Lawrence M. Blatt ,  Scott D. Seiwert ,  Jin Hong

    发明人： Lawrence M. Blatt ,  Scott D. Seiwert ,  Jin Hong

    IPC分类号： A61K38/19 ,  A61K38/21 ,  C07K14/555 ,  C07K14/56

    CPC分类号： C07K14/555 ,  A61K38/00 ,  C07K14/56 ,  C07K14/565 ,  C07K14/57 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/393

    摘要： The present invention provides synthetic Type I interferon receptor polypeptide agonists comprising consensus or hybrid Type I interferon receptor polypeptide agonists, containing one or more native or non-native glycosylation sites. The present invention provides synthetic Type I interferon receptor polypeptide agonists comprising consensus or hybrid Type I interferon receptor polypeptide agonists, containing one or more native or non-native glycosylation sites, as well as erythropoietin and darbepoetin alfa, each of which are linked to a penetrating peptide that facilitates translocation of a substance across a biological barrier as well as pharmaceutical compositions, including oral formulations, of the same. The present invention further provides oral formulations of hyperglycosylated or protease-resistant, hyperglycosylated polypeptide variants, which polypeptide variants lack at least one protease cleavage site found in a parent polypeptide, and thus exhibit increased protease resistance compared to the parent polypeptide, which polypeptide variants further include (1) a carbohydrate moiety covalently linked to at least one non-native glycosylation site not found in the parent protein therapeutic or (2) a carbohydrate moiety covalently linked to at least one native glycosylation site found but not glycosylated in the parent protein therapeutic. The present invention further provides compositions, including oral pharmaceutical compositions, comprising the synthetic Type I interferon receptor polypeptide agonist, the hyperglycosylated polypeptide variant, or the hyperglycosylated, protease-resistant polypeptide variant. The present invention further provides containers, devices, and kits comprising the synthetic Type I interferon receptor polypeptide agonist, the hyperglycosylated polypeptide variant, or the hyperglycosylated, protease-resistant polypeptide variant. The present invention further provides therapeutic methods involving administering an effective amount of an oral pharmaceutical composition comprising a synthetic Type I interferon receptor polypeptide agonist, a hyperglycosylated polypeptide variant, or a hyperglycosylated, protease-resistant polypeptide variant to an individual in need thereof.